Topic resource collection
Approved comparison material connected to this topic.
479 resourcesRead both sides
TB-500 (Thymosin Beta-4) Modulates T-cell differentiation; increases Treg populations in synovial fluid 34% increase in synovial Treg cells; 47% reduction in inflammation scores (Arthritis Research & Therapy, 2023) 5mg subcutaneo…
Before selecting a peptide protocol, understanding how each candidate differs in mechanism, administration, and evidence level prevents mismatched expectations. BPC-157 Nitric oxide modulation, VEGF upregulation, mucosal repair S…
Cerebrolysin Multi-target neurotrophic activation (BDNF, GDNF, NGF) via Trk receptors Moderate (requires IV administration for CNS effect) Restored dendritic spine density to 87% of wild-type in Shank3-deficient mice; normalized …
Tirzepatide Dual GLP-1/GIP agonist. Reduces insulin, slows gastric emptying Strong (Phase 3 RCT, n=412) Insulin-resistant, BMI ≥27 5–15mg weekly SC GI side effects during titration (35% nausea rate) Semaglutide GLP-1 agonist. Imp…
BPC-157 VEGF pathway activation; promotes angiogenesis and fibroblast migration 200–500 mcg/kg daily (animal models); 100–300 mcg daily (human equivalent) Tendons, ligaments, annulus fibrosus of intervertebral discs 28 days at 2–…
Copper Peptides (GHK-Cu) Cytokine suppression, collagen remodeling IL-1β, TNF-α downregulation 40–52% reduction in inflammatory lesions (12 weeks) All skin types; particularly effective for post-inflammatory hyperpigmentation Bes…
Thymalin Thymic epithelial regeneration, T-regulatory cell production Reduces systemic inflammation (inflammaging), stabilizes atherosclerotic plaques 5–10mg subcutaneous, 2x weekly IL-6 reduction 18–22%, Treg count increase 28–3…
P21 BDNF upregulation, neuroprotection Serotonergic neuron resilience, mood stability Preclinical models, limited human data Strong mechanism for luteal-phase mood symptoms; clinical trials needed Cerebrolysin Neurotrophic factor…
BPC-157 VEGF pathway activation; angiogenesis in peritubular capillaries Ischemia-reperfusion injury models; cisplatin nephrotoxicity studies 200-500 mcg subcutaneously daily in rodent models (human equivalent dose unvalidated) E…
Thymalin Immune modulation via thymulin upregulation Reduced inflammatory cytokines and improved CD4+/CD8+ ratios in men >60 with BPH (Advances in Gerontology, 2019) 10mg IM every other day × 10 doses Strongest evidence for immun…
Thymalin Thymic peptide restoration Immune T-cell maturation, autoimmune regulation 10mg subcutaneous every 3–5 days, 10-injection cycle 10–14 days for immune marker changes Best option for perimenopause research focused on immun…
BPC-157 VEGF modulation, angiogenesis regulation, tissue repair Lesion neovascularisation, adhesion formation Preclinical only. In vitro and animal models Strongest theoretical basis for anti-adhesion effects; no human trials in …
Before interpreting this table, understand that peptide research in postpartum populations is limited. Most evidence comes from wound healing, immune reconstitution, or metabolic studies in other contexts, with postpartum applica…
Before selecting a peptide for CTE research, compare the molecular targets each compound addresses, the dosing schedules validated in published TBI models, and the known limitations that affect reproducibility. | Peptide | Primar…
BPC-157 (research peptide) VEGF upregulation, eNOS activation, MMP inhibition Promotes endothelial repair, reduces matrix degradation, improves venous tone Unknown. No long-term human data available Most promising for addressing …
Evidence Level Multiple published wound healing studies in tendon, ligament, dermal models Established cell migration and anti-inflammatory data, primarily in soft tissue injury Strong collagen remodeling evidence, widely studied…
The table below compares the three leading research peptides for REM architecture restoration. Each compound operates through a distinct neurochemical mechanism. Understanding the pathway differences is critical to selecting the …
Before integrating any peptide into a chronic insomnia protocol, understanding mechanism specificity and evidence quality is essential. DSIP (Delta Sleep-Inducing Peptide) Modulates slow-wave sleep architecture; normalizes HPA-ax…
Before reviewing specific peptides, understand that this comparison evaluates research-grade compounds based on preclinical evidence and proposed mechanisms—not clinical trial outcomes in celiac patients. None of these peptides a…
Thymalin Immune modulation via thymic peptide bioregulation Reduces hepatic inflammation that drives cholesterol synthesis 5–10mg subcutaneous 2–3x/week for 8–12 weeks 6–10 weeks for lipid panel changes Best for individuals with …